Proton pump inhibitors: Effective first-line treatment for management of dyspepsia

Digestive Diseases and Sciences

Volumn 52, Issue 4, 2007, Pages 983-987

  Peura, David A ^a   Gudmundson, Jeff ^b   Siepman, Nancy ^b   Pilmer, Betsy L ^b   Freston, James ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Functional dyspepsia; Proton pump inhibitor

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL DISCOMFORT; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DUODENUM ULCER; DYSPEPSIA; HEARTBURN; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH EROSION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DYSPEPSIA; ENZYME INHIBITORS; HUMANS; PATIENT SELECTION; PROTON PUMPS;

EID: 33947586728     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9156-7     Document Type: Article

References (31)

1. Benson V, Marano MA (1998) Current estimates from the National Health Interview Survey, 1995, National Center for Health Statistics. Vital Health Stat 10:199
2. Jones R, Lydeard S (1989) Prevalence of symptoms of dyspepsia in the community. Br Med J 298:30-32
3. Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A (1999) Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/ International Gastroenterology Surveillance Study. Am J Gastroenterol 94(10):2845-2854
4. Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ (2001) Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am J Gastroenterol 96:673-676
5. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJI (1992) Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterol 102:1259-1268
6. Westbrook JI, McIntosh J, Talley NJ (2000) Factors associated with consulting medical or non-medical practitioners for dyspepsia: an Australian population-based study. Aliment Pharmacol Ther 14:1581-1588
7. Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood G, Grender J, Peura D (2004) Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol 2(1):17-21
8. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K (2000) Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108:65-72
9. Robinson M (2001) Dyspepsia: challenges in diagnosis and selection of treatment. Clin Ther 23:1130-1144
10. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B (2000) Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J 321:659-664
11. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D (2003) An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 98(12):2621-2626
12. Laine L, Schoenfeld P, Fennerty MB (2001) Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 134:361-369
13. Hunt RH, Cederberg C, Dent J, et al. (1995) Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 40(2 Suppl):24S-49S
14. Talley NJ, Meineche-Schmidt V, Pare P, et al. (1998) Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trial (the Bond and Opera studies). Aliment Pharmacol Ther 12:1055-1065
15. Peura DA, Kovacs TOG, Metz DC, Siepman N, Pilmer B, Talley NJ (2004) Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 116:740-748
16. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W (1989) Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 2:92-95
17. Blum AL, Talley NJ, O'Morain C, et al. (1998) Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) study group. N Engl J Med 339:1875-1881
18. Axon ATR, Malfertheiner P, Megraud F (2000) Non-ulcer dyspepsia and patient management including diagnosis and treatment. Eur J Gastroenterol Hepatol 12:1053-1056
19. Hession PT, Malagelada J-R (2000) Review article: the initialmanagement of uninvestigated dyspepsia in younger patients-the value of symptom-guided strategies should be reconsidered. Aliment Pharmacol Ther 14:379-388
20. Johnsson F, Weywadt L, Solhaug J-H, Hernqvist H, Bengtsson L (1998) One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 33:15-20
21. DeVault KR, Castell DO (1999) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 94:1434-1442
22. Laine L, Schoenfeld P, Fennerty B (2000) H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: meta-analysis of randomized controlled trials. Gastroenterol 118:A440
23. Jones RH, Baxter G (1997) Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 11(3):541-546
24. Goves J, Oldring JK, Kerr D, Dallara RG, Roffe EJ, Powell JA, Taylor MD (1998) First-line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 12(2):147-157
25. Mason I, Miller LJ, Sheikh RR, Evans WM, Todd PL, Turbitt ML, Taylor MD (1998) The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacidalginate/ranitidine management strategy. Compete Research Group [corrected Aliment Pharmacol Ther 1998 Jun:12(6):589] Aliment Pharmacol Ther 12(3):263-271
26. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. (2002) Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 3(12):1395-1402
27. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ (2004) Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 19(6):631-641
28. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ (2004) The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 127:1329-1337
29. Whitehead WE (1999) Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med 107:33S-40S
30. Holtmann G, Goebell H, Talley NJ (1998) Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 92:954-959
31. Clinical Practice and Practice Economics Committee of the American Gastroenterological Association (1998) American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 114:579-581